Multiple genetic alterations with prognostic significance have been discovered in acute myeloid leukemia (AML). We studied the expression level of two genes, Meningioma1 (MN1) and Phosphatase and Tensin homolog (PTEN) to determine their expression in AML patients and their role as prognostic markers.
METHODS:
The study included 50 cytogenetic normal de novo AML cases and 10 controls, Their level was detected by Real time Reverse Transcription-Polymerase Chain Reaction.
RESULT:
Relative mRNA expression of MN1 was significantly higher (p value < 0.001) and PTEN expression was significantly lower (p value = 0.002). No correlation was found between neither MN1 nor PTEN mRNA expression and overall survival (p value = 0.212 and 0.310) respectively.
CONCLUSION:
Although our study suggests a role for MN1 gene and PTEN genes in AML, we could not recommend their use as routine diagnostic and prognostic markers for AML in Egyptian population.
National Cancer Institute (NCI) Registry. National Cancer Institute statistics, 2010. Department of Biostatistics and Cancer Epidemiology, NCI Cairo, 2010; 63-6.
4.
YanX, MengF, ZhaoH, YangJ. Expression and clinical significance of MN1 and PTEN gene in patients with acute myeloid leukemia. The Chinese-German Journal of Clinical Oncology2011; 10(4): 232-4.
5.
Lekanne DeprezRH, RiegmanPH, GroenNA, WarringaUL, van BiezenNA, MolijnAC, et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene1995; 10(8): 1521-8.
6.
HeuserM, BeutelG, KrauterJ, DohnerK, von NeuhoffN, SchlegelbergerB, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood2006; 108: 3898-905.
7.
GrosveldGC. MN1, a novel player in human AML. Blood Cells Mol Dis.2007; 39(3): 336-9.
8.
KandilciA, SurtelJ, JankeL, NealeG, TerranovaS, GrosveldGC. Mapping of MN1 Sequences Necessary for Myeloid Transformation. PLoS One2013; 8(4): e61706.
9.
GuoaW, SchubbertaS, ChenaJY, ValamehraB, MosessianaS, ShiaH, et al. Suppression of leukemia development caused by PTEN loss. PNAS2011; 108(4): 1409-14.
10.
LeeJO, YangH, GeorgescuMM, DiCristofanoA, MaehamaT, ShiY, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell1999; 99: 323-34.
ZhangJ, GrindleyJC, YinT, JayasingheS, HeXC, RossJT, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature2006; 441: 518-22.
13.
SansalI and SellersWR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J ClinOncol2004; 22: 2954-63.
14.
AbbottRT, TrippS, PerkinsSL, Elerntoba-JohnsonKSJ, LimMS. Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod. Pathol.2003; 16: 607-12.
15.
DöhnerH, EsteyEH, AmadoriS, AppelbaumFR, BüchnerT, BurnettAK, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood2010; 115(3): 453-74.
16.
Van WelyKH, MolijnAC, BuijsA, Meester-SmoorMA, AarnoudseAJ, HellemonsA, et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene2003; 22(5): 699-709.
17.
HeuserM, ArgiropoulosB, KuchenbauerF, YungE, PiperJ, FungS, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood2007; 110(5): 1639-47.
18.
RossME, MahfouzR, OnciuM, LiuHC, ZhouX, SongG, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood2004; 104: 3679-87.
19.
ValkPJ, VerhaakRG, BeijenMA, ErpelinckCA, Barjesteh van Waalwijk van Doorn-KhosrovaniS, BoerJM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med2004; 350(16): 1617-28.
20.
CarellaC, BontenJ, SirmaS, KranenburgTA, TerranovaS, Klein-GeltinkR, et al. MN1 overexpression is an important step in the development of inv(16) AML. Leukemia2007; 21: 1679-90.
21.
XiangL, LiM, LiuY, CenJ, ChenZ, ZhenX, et al. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. AnnHematol.2013 Aug; 92(8): 1063-9.
22.
ArefS, IbrahimL, MorkesH, AzmyE, EbrahimM. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetic (CN-AML). Hematology2013; 18(5): 277-83.
23.
ShenWH, BalajeeAS, WangJ. Essential role for nuclear PTEN in miaintaining chromosomal integrity. Mol Cell2007; 128(1): 157-70.
24.
Blanco-AparicioC, RennerO, LealJF, CarneroA. PTEN, more than the AKT pathway. Carcinogenesis2007; 28: 1379-86.
25.
ZhangS and YuD. PI (3) king apart PTEN's role in cancer. Clin Cancer Res2010; 16: 4325-30.
26.
SongMS, SalmenaL, PandolfiPP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol2012; 13: 283-96.
27.
WangCC, HuaiL, ZhangCP, JiaYJ, LiQH, ChenYR, et al. Study on expression of PTEN gene and its pseudogene PTENP1 in acute leukemia and correlation between them. ZhonghuaXue Ye XueZaZhi2012; 33(11): 896-901.
28.
YangJ, LiuJ, ZhengJ, DuW, HeY, LiuW, et al. A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia. Leukemia2007; 21(9): 2072-4.
29.
TibesR, KornblauSM, QiuY, MoussesSM, RobbinsC, MosesT, et al. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol2008; 140(3): 344-7.
